The Office Evaluation of Weakness

Elliot L Dimberg

doi:10.1055/s-0031-1271307

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2011; 31(1): 115-130
DOI: 10.1055/s-0031-1271307

The Office Evaluation of Weakness

Elliot L. Dimberg¹

¹Department of Neurology, Mayo Clinic, Jacksonville, Florida

Abstract

ABSTRACT

The office evaluation of weakness can be a daunting task. Many different disorders affecting many different parts of the nervous system can manifest with “weakness,” and several nonneurologic conditions may present with complaints of weakness. It is the job of the neurologist to determine whether a patient has neurologic weakness or suffers simply from fatigue. The physician then must properly localize the pathophysiologic site of weakness. The author focuses on neuromuscular causes of weakness affecting muscle, the neuromuscular junction, peripheral nerve, or the anterior horn cell. General historical and examination clues to localization will be discussed. A localization-based evaluation will be outlined, with more specific recommendations regarding the evaluation of a few specific disorders offered. Localization-specific laboratory, electrodiagnostic, imaging, and pathologic investigations will be presented.

KEYWORDS

Weakness - myopathy - myasthenia gravis - multifocal motor neuropathy - amyotrophic lateral sclerosis

Volltext

Referenzen

REFERENCES

1 Merriam-Webster. Fatique. Available at: http://www.merriam-webster.com/medlineplus/fatigue Accessed June 1, 2010
2 Baker S B, Worthley L I. The essentials of calcium, magnesium and phosphate metabolism: part II. Disorders. Crit Care Resusc. 2002; 4 (4) 307-315
3 Riggs J E. Neurologic manifestations of electrolyte disturbances. Neurol Clin. 2002; 20 (1) 227-239, vii
4 Alshekhlee A, Kaminski H J, Ruff R L. Neuromuscular manifestations of endocrine disorders. Neurol Clin. 2002; 20 (1) 35-58, v–vi
5 Bordelon P, Ghetu M V, Langan R C. Recognition and management of vitamin D deficiency. Am Fam Physician. 2009; 80 (8) 841-846
6 Ziambaras K, Dagogo-Jack S. Reversible muscle weakness in patients with vitamin D deficiency. West J Med. 1997; 167 (6) 435-439
7 Hinshaw D B, Carnahan J M, Johnson D L. Depression, anxiety, and asthenia in advanced illness. J Am Coll Surg. 2002; 195 (2) 271-277 discussion 277-278
8 Ruttenber A J, McAnally H B, Wetli C V. Cocaine-associated rhabdomyolysis and excited delirium: different stages of the same syndrome. Am J Forensic Med Pathol. 1999; 20 (2) 120-127
9 Walsh R J, Amato A A. Toxic myopathies. Neurol Clin. 2005; 23 (2) 397-428
10 Dresser L P, Massey E W, Johnson E E, Bossen E. Ipecac myopathy and cardiomyopathy. J Neurol Neurosurg Psychiatry. 1993; 56 (5) 560-562
11 Mastaglia F L. Drug induced myopathies. Pract Neurol. 2006; 6 4-13
12 Gaist D, Rodríguez L A, Huerta C, Hallas J, Sindrup S H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001; 12 (5) 565-569
13 Bradley W G, Lassman L P, Pearce G W, Walton J N. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970; 10 (2) 107-131
14 Srinivasan J, Wu C J, Amato A A. Inflammatory myopathy associated with imatinib mesylate therapy. J Clin Neuromuscul Dis. 2004; 5 (3) 119-121
15 Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis. 2002; 3 (3) 97-105
16 Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy. 2004; 24 (12) 1784-1792
17 Casado E, Gratacós J, Tolosa C et al.. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006; 65 (3) 385-390
18 Kwon J-B, Kleiner A, Ishida K, Godown J, Ciafaloni E, Looney Jr R J. Hydroxychloroquine-induced myopathy. J Clin Rheumatol. 2010; 16 (1) 28-31
19 Authier F J, Chariot P, Gherardi R K. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve. 2005; 32 (3) 247-260
20 Tunn U W, Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis. 2009; 12 (1) 83-87
21 Sobaci G, Erdem U, Durukan A H et al.. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology. Available at: http://dx.doi.org/10.1016/j.ophtha.2009.11.022 Accessed June 1, 2010
22 Shaiova L. The management of opioid-related sedation. Curr Pain Headache Rep. 2005; 9 (4) 239-242
23 Aapro M S, Cella D, Zagari M. Age, anemia, and fatigue. Semin Oncol. 2002; 29 (3, Suppl 8) 55-59
24 Meeus M, Mistiaen W, Lambrecht L, Nijs J. Immunological similarities between cancer and chronic fatigue syndrome: the common link to fatigue?. Anticancer Res. 2009; 29 (11) 4717-4726
25 Clauw D J. Fibromyalgia: an overview. Am J Med. 2009; 122 (12, Suppl) S3-S13
26 Mioxham J, Jolley C. Breathlessness, fatigue and the respiratory muscles. Clin Med. 2009; 9 (5) 448-452
27 Shizukuda Y, Plummer S L, Harrelson A. Customized exercise echocardiography: beyond detection of coronary artery disease. Echocardiography. 2010; 27 (2) 186-194
28 Newton J L. Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis. 2010; 28 (1) 214-219
29 Stenholm S, Kronholm E, Sainio P et al.. Sleep-related factors and mobility in older men and women. J Gerontol A Biol Sci Med Sci. 2010; 65 (6) 649-657
30 Dhruva A, Dodd M, Paul S M et al.. Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nurs. 2010; 33 (3) 201-212
31 Vernon S D, Whistler T, Cameron B, Hickie I B, Reeves W C, Lloyd A. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus. BMC Infect Dis. 2006; 6 15
32 Banning M. Influenza: incidence, symptoms and treatment. Br J Nurs. 2005; 14 (22) 1192-1197
33 Dalakas M C. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009; 80 (8) 832-838
34 Toyooka K, Fujimura H. Iatrogenic neuropathies. Curr Opin Neurol. 2009; 22 (5) 475-479
35 Members of the Mayo Clinic Department of Neurology, Mayo Clinic and Mayo Foundation .Mayo Clinic Examinations in Neurology. 7th ed. St. Louis, MO: Mosby; 1998
36 The Guarantors of Brain. Aids to the Examination of the Peripheral Nervous System. 4th ed. Edinburgh: W.B. Saunders; 2000
37 Tawil R, Van Der Maarel S M. Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2006; 34 (1) 1-15
38 Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010; 81 (4) 358-367
39 van Adel B A, Tarnopolsky M A. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis. 2009; 10 (3) 97-121
40 Bogousslavsky J, Perentes E, Regli F, Deruaz J P. Polymyositis with severe facial involvement. J Neurol. 1982; 228 (4) 277-281
41 Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Curr Neurol Neurosci Rep. 2009; 9 (1) 76-82
42 Ptáĉek L J, Tawil R, Griggs R C et al.. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology. 1994; 44 (8) 1500-1503
43 Sanders D B, El-Salem K, Massey J M, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003; 60 (12) 1978-1980
44 Pasnoor M, Wolfe G I, Nations S et al.. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010; 41 (3) 370-374
45 O'Neill J H, Murray N MF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988; 111 (Pt 3) 577-596
46 Katz J S, Wolfe G I, Bryan W W, Tintner R, Barohn R J. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1998; 50 (2) 470-475
47 O'Suilleabhain P, Low P A, Lennon V A. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology. 1998; 50 (1) 88-93
48 Reed U C. Congenital muscular dystrophy. Part I: a review of phenotypical and diagnostic aspects. Arq Neuropsiquiatr. 2009; 67 (1) 144-168
49 Sewry C A, Jimenez-Mallebrera C, Muntoni F. Congenital myopathies. Curr Opin Neurol. 2008; 21 (5) 569-575
50 Ozawa E, Noguchi S, Mizuno Y, Hagiwara Y, Yoshida M. From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy. Muscle Nerve. 1998; 21 (4) 421-438
51 Norwood F, de Visser M, Eymard B, Lochmüller H, Bushby K. EFNS Guideline Task Force . EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. Eur J Neurol. 2007; 14 (12) 1305-1312
52 Feldman B M, Rider L G, Reed A M, Pachman L M. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008; 371 (9631) 2201-2212
53 Selcen D, Ohno K, Engel A G. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain. 2004; 127 (Pt 2) 439-451
54 Amato A A, Barohn R J. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009; 80 (10) 1060-1068
55 Miller T M, Dias da Silva M R, Miller H A et al.. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004; 63 (9) 1647-1655
56 Day J W, Ricker K, Jacobsen J F et al.. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003; 60 (4) 657-664
57 Hoffman E P, Fischbeck K H, Brown R H et al.. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med. 1988; 318 (21) 1363-1368
58 Guglieri M, Magri F, D'Angelo M G et al.. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat. 2008; 29 (2) 258-266
59 Pautas E, Chérin P, Piette J C et al.. Features of polymyositis and dermatomyositis in the elderly: a case-control study. Clin Exp Rheumatol. 2000; 18 (2) 241-244
60 Wong E T, Cobb C, Umehara M K et al.. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol. 1983; 79 (5) 582-586
61 Wakefield S E, Dimberg E L, Moore S A, Tseng B S. Dystrophinopathy presenting with arrhythmia in an asymptomatic 34-year-old man: a case report. J Med Case Reports. 2009; 3 8625
62 Eymard B, Brouet J C, Collin H, Chevallay M, Bussel A, Fardeau M. Late-onset rod myopathy associated with monoclonal gammopathy. Neuromuscul Disord. 1993; 3 (5-6) 557-560
63 Milone M, Katz A, Amato A A et al.. Sporadic late onset nemaline myopathy responsive to IVIg and immunotherapy. Muscle Nerve. 2010; 41 (2) 272-276
64 Sundblad A, Porwit A, Ostad M et al.. Antibody reactivities to skeletal muscle proteins in a patient with lambda light chain secreting multiple myeloma, generalised amyloidosis and rhabdomyolysis. Eur J Haematol. 2001; 67 (3) 189-193
65 Chapin J E, Kornfeld M, Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve. 2005; 31 (2) 266-272
66 Wexler R K, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview. Am Fam Physician. 2009; 79 (9) 778-784
67 Engel A G, Ohno K, Sine S M. Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve. 2003; 27 (1) 4-25
68 Engel A G, Shen X M, Selcen D, Sine S M. Further observations in congenital myasthenic syndromes. Ann N Y Acad Sci. 2008; 1132 104-113
69 Conti-Fine B M, Milani M, Kaminski H J. Myasthenia gravis: past, present, and future. J Clin Invest. 2006; 116 (11) 2843-2854
70 Grob D. Course and management of myasthenia gravis. J Am Med Assoc. 1953; 153 (6) 529-532
71 Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008; 37 (2) 141-149
72 D'Amelio M, Di Benedetto N, Ragonese P et al.. Dropped head as an unusual presenting sign of myasthenia gravis. Neurol Sci. 2007; 28 (2) 104-106
73 Nations S P, Wolfe G I, Amato A A, Jackson C E, Bryan W W, Barohn R J. Distal myasthenia gravis. Neurology. 1999; 52 (3) 632-634
74 Renard D, Castelnovo G, Labauge P. Distal myasthenia gravis. Acta Neurol Belg. 2008; 108 (3) 107-108
75 Kim W H, Kim J H, Kim E K et al.. Myasthenia gravis presenting as isolated respiratory failure: a case report. Korean J Intern Med. 2010; 25 (1) 101-104
76 McConville J, Farrugia M E, Beeson D et al.. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004; 55 (4) 580-584
77 Evoli A, Tonali P A, Padua L et al.. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003; 126 (Pt 10) 2304-2311
78 Larner A J. The place of the ice pack test in the diagnosis of myasthenia gravis. Int J Clin Pract. 2004; 58 (9) 887-888
79 Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006; 16 (7) 459-467
80 Meriggioli M N, Sanders D B. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil. 2005; 84 (8) 627-638
81 Howard Jr F M, Lennon V A, Finley J, Matsumoto J, Elveback L R. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987; 505 526-538
82 Chan K H, Lachance D H, Harper C M, Lennon V A. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007; 36 (5) 651-658
83 Kiessling W R, Finke R, Kotulla P, Schleusener H. Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis. Acta Endocrinol (Copenh). 1982; 101 (1) 41-46
84 Chagnac Y, Hadani M, Goldhammer Y. Myasthenic crisis after intravenous administration of iodinated contrast agent. Neurology. 1985; 35 (8) 1219-1220
85 Richard V S, Al-Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine?. Hematology. 2007; 12 (4) 359-360
86 Keesey J C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004; 29 (4) 484-505
87 Skeie G O, Apostolski S, Evoli A et al.. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2006; 13 (7) 691-699
88 Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009; 16 (2) 246-250
89 Muscle Study Group . A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008; 71 (6) 394-399
90 Sanders D B, Hart I K, Mantegazza R et al.. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008; 71 (6) 400-406
91 Hehir M K, Burns T M, Alpers J, Conaway M R, Sawa M, Sanders D B. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010; 41 (5) 593-598
92 Gronseth G S, Barohn R J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55 (1) 7-15
93 Masaoka A, Yamakawa Y, Niwa H et al.. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg. 1996; 62 (3) 853-859
94 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy .Available at: http://clinicaltrials.gov/ct2/show/study/NCT00294658 Accessed June 4, 2010
95 Tim R W, Massey J M, Sanders D B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000; 54 (11) 2176-2178
96 Lennon V A, Lambert E H. Autoantibodies bind solubilized calcium channel-ω-conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myasthenic syndrome. Mayo Clin Proc. 1989; 64 (12) 1498-1504
97 McEvoy K M, Windebank A J, Daube J R, Low P A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989; 321 (23) 1567-1571
98 Wirtz P W, Verschuuren J J, van Dijk J G et al.. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009; 86 (1) 44-48
99 Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 2001; 115 (1-2) 4-18
100 Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology. 2007; 69 (17) 1680-1687
101 Taylor B V, Wright R A, Harper C M, Dyck P J. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve. 2000; 23 (6) 900-908
102 Magistris M, Roth G. Motor neuropathy with multifocal persistent conduction blocks. Muscle Nerve. 1992; 15 (9) 1056-1057
103 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology. 1992; 42 (3 Pt 1) 506-509
104 Olney R K. American Association of Electrodiagnostic Medicine . Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve Suppl. 1999; 8 (Suppl 8) S225-S229
105 Olney R K, Lewis R A, Putnam T D, Campellone Jr J V. American Association of Electrodiagnostic Medicine . Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve. 2003; 27 (1) 117-121
106 Pestronk A, Cornblath D R, Ilyas A A et al.. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988; 24 (1) 73-78
107 Nobile-Orazio E, Cappellari A, Meucci N et al.. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry. 2002; 72 (6) 761-766
108 Chaudhry V, Corse A M, Cornblath D R et al.. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993; 33 (3) 237-242
109 Azulay J P, Blin O, Pouget J et al.. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994; 44 (3 Pt 1) 429-432
110 Van den Berg L H, Kerkhoff H, Oey P L et al.. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995; 59 (3) 248-252
111 Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology. 2000; 55 (9) 1256-1262
112 Léger J M, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001; 124 (Pt 1) 145-153
113 Baumann A, Hess C W, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol. 2009; 256 (4) 608-614
114 Krarup C, Stewart J D, Sumner A J, Pestronk A, Lipton S A. A syndrome of asymmetric limb weakness with motor conduction block. Neurology. 1990; 40 (1) 118-127
115 Feldman E L, Bromberg M B, Albers J W, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991; 30 (3) 397-401
116 Tan E, Lynn D J, Amato A A et al.. Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol. 1994; 51 (2) 194-200
117 Brannagan III T H, Alaedini A, Gladstone D E. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve. 2006; 34 (2) 246-250
118 Strong M J, Grace G M, Freedman M et al.. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10 (3) 131-146
119 Brooks B R, Miller R G, Swash M, Munsat T L. World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1 (5) 293-299
120 Fisher M, Mateer J E, Ullrich I, Gutrecht J A. Pyramidal tract deficits and polyneuropathy in hyperthyroidism, Combination clinically mimicking amyotrophic lateral sclerosis. Am J Med. 1985; 78 (6 Pt 1) 1041-1044
121 Jackson C E, Amato A A, Bryan W W, Wolfe G I, Sakhaee K, Barohn R J. Primary hyperparathyroidism and ALS: is there a relation?. Neurology. 1998; 50 (6) 1795-1799
122 Weihl C C, Lopate G. Motor neuron disease associated with copper deficiency. Muscle Nerve. 2006; 34 (6) 789-793
123 Di Rocco A, Simpson D M. AIDS-associated vacuolar myelopathy. AIDS Patient Care STDS. 1998; 12 (6) 457-461
124 Hemmer B, Glocker F X, Kaiser R, Lücking C H, Deuschl G. Generalised motor neuron disease as an unusual manifestation of Borrelia burgdorferi infection. J Neurol Neurosurg Psychiatry. 1997; 63 (2) 257-258
125 Baud P, Parant E, Loison F, Ménage J J. [IgM kappa lymphoma with antisulfatide antibodies revealed by cervical motor neuropathy simulating amyotrophic lateral sclerosis]. Rev Med Interne. 1998; 19 (4) 275-278
126 Miller R G, Jackson C E, Kasarskis E J Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009; 73 (15) 1218-1226
127 Miller R G, Jackson C E, Kasarskis E J Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009; 73 (15) 1227-1233

Elliot L DimbergM.D.

Department of Neurology, Mayo Clinic in Florida

4500 San Pablo Road, Jacksonville, FL 32224

eMail: Dimberg.Elliot@mayo.edu